September is Pulmonary Fibrosis (PF) Awareness Month. During this month, health charities, research institutes and support groups around the world provide information about Pulmonary Fibrosis. Pulmonary fibrosis is a progressive, incurable disease that affects the tissues in the lungs resulting in lung scarring. Overtime, this leads to a decline in lung function. Sufferers will notice […]
Category: Uncategorized
Exercise training in idiopathic pulmonary fibrosis: is it of benefit?
Abstract Exercise is a well-documented safe and effective intervention for prevention and rehabilitation of chronic diseases. Idiopathic pulmonary fibrosis (IPF) is a chronic deadly lung disease associated with severe signs and symptoms, exercise intolerance, diminished quality of life and poor prognosis. In the short term, supervised exercise training programmes have demonstrated clinical benefits in improving […]
Evaluation for clinical benefit of metformin in patients with idiopathic pulmonary fibrosisand type 2 diabetes mellitus: a national claims‑based cohort analysis
Abstract BackgroundIdiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with high morbidity and limited treatment options. Type 2 diabetes mellitus (T2DM) is a common comorbid illness among patients with IPF and is often treated with metformin, the first-line agent in the management of T2DM. There is growing evidence demonstrating metformin’s anti-fibrotic properties; however, […]
Plasticity towards Rigidity: A Macrophage Conundrum in
Pulmonary Fibrosis
Abstract: Idiopathic pulmonary fibrosis (IPF) is a progressive, chronic, and ultimately fatal diffuse parenchymal lung disease. The molecular mechanisms of fibrosis in IPF patients are not fully understood and there is a lack of effective treatments. For decades, different types of drugs such as immunosuppressants and antioxidants have been tested, usually with unsuccessful results. Although […]
TIPAL
TIPAL: The effectiveness and risks of Treating people with Idiopathic Pulmonary fibrosis with the Addition of Lansoprazole, a randomised placebo-controlled multi-centre clinical trial The TIPAL research study is focusing on treating idiopathic pulmonary fibrosis (IPF) with the addition of lansoprazole. Lansoprazole reduces the amount of acid your stomach makes. It’s used for indigestion, heartburn, acid reflux and gastroesophageal-reflux-disease (GORD). Lansoprazole is […]
Targeting Cpt1a-Bcl-2 interaction modulates apoptosis resistance and fibrotic remodeling
Abstract The mitochondrial calcium uniporter (MCU) regulates metabolic reprogramming in lung macrophages and the progression of pulmonary fibrosis. Fibrosis progression is associated with apoptosis resistance in lung macrophages; however, the mechanism(s) by which apoptosis resistance occurs is poorly understood. Here, we found a marked increase in mitochondrial B-cell lymphoma-2 (Bcl-2) in lung macrophages from subjects […]
UK Petition, March 2023
Increase funding for treatment of pulmonary fibrosis & interstitial lung disease Ask the Government to prioritise funding for Pulmonary Fibrosis (PF) and interstitial lung disease services. PF is terminal and kills approximately 8,000 people a year. It has a survival rate worse than many cancers. Increasing funding and creating a care pathway equal to cancer […]
Pulmonary Fibrosis Research and Education Hub
Welcome to the Pulmonary Fibrosis Research and Education Hub which is run and maintained by the Natonal Wellbeing Service Ltd.